Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact email@example.com.
SOURCE GenomeDx Biosciences
SAN DIEGO, May 8, 2014 /PRNewswire/ -- GenomeDx Biosciences announced today that the company's Decipher® Prostate Cancer Classifier will be featured in multiple sessions during the American Urological Association (AUA) Annual Meeting taking place May 16-21 in Orlando, FL. Two data presentations will detail validation studies supporting the use of Decipher to predict risk of metastasis in men following prostate surgery. Decipher has also been included in independent CME and educational courses at AUA 2014. The Decipher test and a mobile app for urologists will also be the subject of an AUA Skills Challenge conducted at the GenomeDx exhibit booth.
AUA Skills Challenge
GenomeDx will be participating in the AUA's first annual Skills Challenge, hosting a hands-on challenge at the company's exhibit booth that will allow physicians to test drive the company's UroSketch 3DTM mobile app and learn more about how genomic risk assessment tools might fit within their practice. The challenge will be held at the GenomeDx booth (# 1775) at the conference where physicians can also learn more about how the Decipher test and the company's soon to be launched second mobile application can transform patient management.
Decipher® Prostate Cancer Data Presentations
Abstract Title: "Independent validation of a genomic classifier in an at risk population of men conservatively managed after radical prostatectomy"
Date and Time: Tuesday, May 20, 1:00 p.m. to 3:00 p.m. EDT
Abstract #: MP74-06
Abstract Title: "Validation of a genomic classifier for predicting clinical progression following post-operative radiation therapy in high-risk prostate cancer"
Date and Time: Tuesday, May 20, 3:30 p.m. to 5:30 p.m. EDT
Abstract #: MP79-01
Genomic Testing Educational Events
Several educational events will cover ground on the impact and use of genomic tests, including Decipher. Unless noted, these events are not sponsored by GenomeDx.
GenomeDx will also present new data on validation of a 15 gene bladder cancer classifier for predicting post cystectomy cancer recurrence. The presentation (abstract # MP39-09) will occur on Sunday, May 18 during the Basic Research IV Bladder Cancer Poster Session taking place between 3:30 p.m. and 5:30 p.m. EDT in W 3014A. This poster has also been selected for display at the AUA/Urology Care Foundation's Research Honors Awards Program reception on May 16.
The Decipher® Prostate Cancer Classifier directly measures a patient's biological risk of developing metastatic prostate cancer. By assessing the activity of multiple genomic markers associated with metastatic disease, Decipher provides information about the aggressiveness of a patient's tumor - information distinct from that provided by PSA and other clinical tools. Decipher continues to demonstrate that it can accurately predict aggressive disease and help physicians make more informed treatment decisions for men with prostate cancer.
Decipher is covered by multiple private insurance plans and is available to eligible US patients through their physicians. To learn more about ordering the Decipher test please visit www.deciphertest.com.
About GenomeDx Biosciences
GenomeDx Biosciences is focused on transforming patient management by putting usable genomic information in the hands of patients and their physicians. GenomeDx has developed the Decipher® Prostate Cancer Classifier, the first and only commercially available genomic test that predicts the risk of developing metastatic prostate cancer independently of PSA and other conventional risk assessment tools. GenomeDx is based in San Diego, California and Vancouver, British Columbia. To learn more visit www.genomedx.com.
Video - http://youtu.be/LQEgPoXO9vM
©2012 PR Newswire. All Rights Reserved.